Article Type: Original Articles
Patients with First Episode Psychosis and Chronic Schizophrenia may not Differ in Mean Platelet Volume Affecting its Value as an Indicator of Cardiovascular Disease
Musa Sahpolat, Mustafa Ari


Objective: The aim of the present study was to examine differences in terms of mean platelet volume (MPV) in patients with first episode psychosis, chronic schizophrenia, and psychiatrically healthy controls and to determine the potential value of MPV for cardiovascular disorders in patients with psychotic disorders.

Methods: A total number of 32 patients with first episode psychosis, 44 patients with chronic schizophrenia, and 43 randomly selected weight- and body mass index-matched psychiatrically healthy controls who presented to the Psychiatry Outpatient Clinic were included. The Positive and Negative Syndrome Scale (PANSS) was administered to the patients group. The body mass index (BMI) was calculated and MPV was measured for each subject.

Results: The mean MPV level was 9.38±1.00 fL in patients with first episode psychosis, 9.60±1.02 fL in patients with chronic schizophrenia, and 9.2±0.94 fL in psychiatrically healthy controls group. MPV levels were not significantly different between the three groups. There were no statistically significant differences between the three groups in terms of platelet count or BMI. There were no statistically significant correlations between the MPV levels and total PANSS scores in the patients groups.

Conclusions: To the best of our knowledge, the present study was the first to evaluate the MPV levels in patients with first episode psychosis. We consider that it is not appropriate for MPV to be used as an indicator for CVDs in patients with psychosis. Better-designed and more advanced studies are necessary to determine the exact function of platelets and the importance of MPV in patients with first episode psychosis and chronic schizophrenia.

REFERENCES

1.Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007;116(5):317-33.

2.Oud MJ, Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general practice: Their prevalence and health care. BMC Fam Pract 2009;10:32.

3.Himelhoch S, Leith J, Goldberg R, Kreyenbuhl J, Medoff D, Dixon L. Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smoke. Gen Hosp Psychiatry 2009;31(1):30-2.

4.Slavka G, Perkmann T, Haslacher H, Greisenegger S, Marsik C, Wagner OF, et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol 2011;31(5):1215-8.

5.Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005;46(2):284-90.

6.Ragolsky M, Shimon H, Shalev H, Weizman A, Rubin E. Suicidal thoughts are associated with platelet counts in adolescent inpatients. J Child Adolesc Psychopharmacol 2013;23(1):49-53.

7.Ataoglu A, Canan F. Mean platelet volume in patients with major depression: effect of escitalopram treatment. J Clin Psychopharmacol 2009;29(4):368-71.

8.Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand 1996;94(3):198-204.

9.Wysokiński A, Szczepocka E. Platelet parameters (PLT, MPV, P-LCR) in patients with schizophrenia, unipolar depression and bipolar disorder. Psychiatry Res 2016;237:238-45.

10.Canan F, Dikici S, Kutlucan A, Celbek G, Coskun H, Gungor A, et al. Association of mean platelet volume with DSM-IV major depression in a large community-based population: the MELEN study. J Psychiatr Res 2012;46:298-302.

11.Yorbik O, Mutlu C, Tanju IA, Celik D, Ozcan O. Mean platelet volume in children with attention deficit hyperactivity disorder. Med Hypotheses 2014;82(3):341-5.

12.Kokacya MH, Copoglu US, Ari M, Sahpolat M, Ulutas KT, Kivrak Y. Increased Mean Platelet Volume in Patients with Depression. J Clin Anal Med 2015;6:13-5.

13.Kokacya MH, Copoglu US, Kivrak Y, Ari M, Sahpolat M, Ulutas KT. Increased mean platelet volume in patients with panic disorder. Neuropsychiatr Dis Treat 2015;11:2629-33.

14.Kalelioglu T, Akkus M, Karamustafalioglu N, Genc A, Genc ES, Cansiz A, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as infl ammation markers for bipolar disorder. Psychiatry Res 2015;228(3):925–7.

15.Lee J, Powell V, Remington G. Mean platelet volume in schizophrenia unaltered after 1year of clozapine exposure. Schizophr Res 2014;157(1-3):134-6.

16.Gogcegoz Gul I, Eryilmaz G, Ozten E, Hizli Sayar G. Decreased mean platelet volume in panic disorder. Neuropsychiatr Dis Treat 2014;10:1665-9.

17.van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 2010;121(1-3):193-8.

18.Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 2007;68(6):899-907.

19.Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010;119(1-3):101-9.

20.De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res 2008;101(1-3):295-303.

21.Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 2010;10(3):209-16.

22.Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166(2):152-63.

23.Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol Clin 2001;16(3):229-36.

24.Dietrich-Muszalska A, Olas B. The changes of aggregability of blood platelets in schizophrenia. World J Biol Psychiatry 2009;10(2):171-6.

25.Coban E, Ozdogan M, Yazicioglu G and Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005;59(8):981-2.

26.Cikrikcioglu MA, Celik K, Ekinci I, Nasifov M, Toprak AE, Cetin G, Genc S. Mean Platelet Volume in Heterozygous Beta Thalassaemia. Acta Haematol 2017;137(2):100-5.

27.Kodiatte TA, Manikyam UK, Rao SB, et al. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians 2012;4(1):5-9.

28.Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004;15(8):475-8.

29.De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8(2):114-26.

30.De Clerck F, Somers Y, Mannaert E, Greenspan A, Eerdekens M. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin Ther. 2004;26(8):1261-73.

31.Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001;179:63-6.

32.Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000;356(9237):1219-23.

33.Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995;3:64-75.

34.Yao JK, van Kammen DP, Moss HB, Sokulski DE. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia. Psychiatry Res 1996;63(2-3):123-32.

35.Dietrich-Muszalska A. Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies. Psych Psychol Klin. 2004;4:215-23.

36.Yao JK, Magan S, Sonel AF, Gurklis JA, Sanders R, Reddy RD. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2004;71(3):171-6.

37.Parakh K, Sakhuja A, Bhat U, Ziegelstein RC. Platelet function in patients with depression. South Med J 2008;101(6):612-7.

38.Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993;60(6): 2319-22.

39.Sumiyoshi T, Bubenikova-Valesova V, Horacek J, Bert B. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther 2008;25(10):1037-56.

40.Dean B, Pavey G, Thomas D, Scarr E. Cortical serotonin7,1D and 1F receptors: effect of schizophrenia, suicide and antipychotic drug treatment. Schizophr Res 2006;88(1-3):265-74.

41.Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 1992;14(4):281-7.

42.Martin J, Shaw T, Heggie J, Penington D. Measurement of the density of human platelets and its relationship to volume. Br J Haematol 1983;54(3):337-52.

43.Thompson CB, Jakubowski JA. The pathophysiology and clinical relevance of platelet heterogeneity. Blood 1988;72(1):1-8.



Key words: Chronic schizophrenia, first attack psychosis, mean platelet volume
Psychiatry and Behavioral Sciences 2019;9(4):166-171
Online ISSN: 2636-834X
Creative Commons License This work is licensed under a Creative Commons Attribution 3.0 Unported License